RxDoctor Payments DataLook up a doctor →

Amit Bhanvadia, MD

Gastroenterology · Anaheim, CANPI 1861751083

Payments from drug & device makers

$1,682,658in general payments, 2019–2025

Across 705 payments — averaging $2386.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$666K
  • Boehringer Ingelheim International GmbH$323K
  • AstraZeneca$240K
  • Regeneron$149K
  • Bausch Health US, LLC$105K
  • Bristol Myers Squibb$76K
  • plus $123K from 25 others
$16,649in research payments, 2019–2025

Across 3 payments — averaging $5549.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$16K
  • Eli Lilly$388

What the payments were for

  • Food & beverage$5,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,682,658 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$57,329
Medicare patients
227
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl17$287
Famotidine13$67

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →